CAR-T Commercialization Strategies: Views From Novartis And Kite

At recent industry events, Novartis and Kite Pharma highlighted opportunities and addressed challenges they face as they prepare to commercialize their CAR-T therapies. A report from Datamonitor Healthcare.

T-cells attacking cancer_1200x675

In regenerative medicine, a major inflection point has been reached in chimeric antigen receptor T-cell (CAR-T) therapy, a personalized immune-based approach to treating various hematological cancers. CAR-T therapy involves the extraction of autologous T cells, which areare then genetically engineered to express CAR and reintroduced back into the patient, where the cells are expected to target cancer cells. The US Food and Drug Administration approved the first such CAR-T product, Novartis AG's Kymriah (tisagenlecleucel-t), on August 30, 2017, and the next therapy soon followed with the approval of Kite Pharma Inc.'s Yescarta (axicabtagene ciloleucel; axi-cel) on October 18, 2017. Being the first, Kymriah's approval clearly marks a milestone, but as David DiGiusto, PhD, executive director of stem cells and cellular therapeutics operations in pediatric transplantation and regenerative medicine at Stanford University, expressed at the September 2017 KNect365 Cell & Gene Therapy (CGT) Bioprocessing & Commercialization meeting in Boston, this is only really the dawn of discovery, and is the start of a long road in effectively and profitably marketing these types of advanced therapies. At the CGT meeting in September 2017 and at the Alliance for Regenerative Medicine (ARM) Meeting on the Mesa in San Diego in October 2017, both Novartis and Kite, as well as other stakeholders, discussed various aspects of manufacturing and commercialization that will impact their success in the CAR-T market.

Kymriah's approval is revolutionary for many reasons. According to DiGiusto, it showed that cell therapies can become viable medicines, especially...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

IMMA Starts A Silent Revolution By Making IVF Journey Digital, Predictable And At Home

 
• By 

IMMA’s transvaginal at-home ovarian stimulation monitoring system using ultrasound and AI image analysis increases the chances of early IVF success. It won the Biomed Israel 2025 IVD start-up showcase award. Further potential applications could follow, cofounder/CEO Beatrice Chemla told In Vivo.

CRL Trio Brings Shifting Sand To Regenerative Medicine Regulation

 

Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.

When Simple Is Best: A Pre-Term Birth Device To End The ‘Silent Emergency’

 
• By 

The Lioness non-surgical silicon ring implant is designed to put an end to pre-term births, sparing maternal anguish and saving health system costs. PregnanTech won the Biomed Israel 2025 medtech start-up award, and Limor Sandach told In Vivo how a non-digital technology beat off stiff competition.

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By 

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

More from In Vivo

When VC Steps Back: Finding Alternative Biotech Funding

 
• By 

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Podcast: Inside MoonLake’s Fast-Track Vision And $500m Deal

 
• By 

MoonLake Immunotherapeutics is racing ahead in the biotech space with its innovative nanobody SLK and a transformative $500m non-dilutive financing deal. In this episode, its CEO and CFO discuss the company’s rapid clinical progress, financial strategy and ambitions to reshape inflammatory disease.

When Simple Is Best: A Pre-Term Birth Device To End The ‘Silent Emergency’

 
• By 

The Lioness non-surgical silicon ring implant is designed to put an end to pre-term births, sparing maternal anguish and saving health system costs. PregnanTech won the Biomed Israel 2025 medtech start-up award, and Limor Sandach told In Vivo how a non-digital technology beat off stiff competition.